Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 6UNKNOWN 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 1

Interventions

Paclitaxel 7Cisplatin 6Radiation 4Carboplatin 4tislelizumab 3Surgical Procedures, Operative 3Radiotherapy 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Platinum Compounds 2Endoscopic Mucosal Resection 2Drug Therapy 2Albumin-Bound Paclitaxel 2nedaplatin 1lobaplatin 1Tranexamic Acid 1Thalidomide 1TP protocol 1Stents 1Standard of Care 1Oxaliplatin 1Nutrition Assessment 1Neoadjuvant Therapy 1Muscle Stretching Exercises 1Indocyanine Green 1Heart Rate 1Fluorouracil 1Exercise 1Epinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Esophageal Neoplasms × nedaplatin × Clear all
NCT07046221 2025-07-20

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

Fujian Cancer Hospital

Phase 2 Not yet recruiting
60 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡